ALNY
Alnylam Pharmaceuticals, Inc.$305.77-2.74 (-0.89%)Prev Close$308.51·MCap$41.24B·P/E135.87·Vol192.2K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
39
$104.46M
◆
Net Activity
Net Seller
$104.46M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Alnylam Pharmaceuticals, Inc. (ALNY) has been exclusively selling, with 0 insider purchases totaling $0.00 and 39 insider sales totaling $104.46M. The most recent insider transaction was by McLaughlin Melissa (officer: Chief Human Resources Officer), who sold $1.27M worth of shares on Apr 7, 2026. Alnylam Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $41.24B.
ALNY Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 7, 2026 | McLaughlin Melissa | officer: Chief Human Resources Officer | Sell | 3,910 | $325.92 | $1.27M | 13,088 |
| Mar 6, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 1,291 | $323.54 | $417.7K | 21,831 |
| Mar 6, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 4,713 | $323.53 | $1.52M | 23,300 |
| Mar 6, 2026 | Greenstreet Yvonne | director, officer: Chief Executive Officer | Sell | 2,933 | $323.08 | $947.6K | 98,493 |
| Mar 6, 2026 | Poulton Jeffrey V. | officer: EVP, Chief Financial Officer | Sell | 2,468 | $323.08 | $797.4K | 64,159 |
| Mar 6, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 2,309 | $323.08 | $746.0K | 36,500 |
| Mar 2, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 4,627 | $331.34 | $1.53M | 26,629 |
| Feb 17, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 4,000 | $321.24 | $1.28M | 23,305 |
| Feb 17, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 2,242 | $310.08 | $695.2K | 24,848 |
| Feb 17, 2026 | Greenstreet Yvonne | director, officer: Chief Executive Officer | Sell | 13,916 | $310.08 | $4.32M | 85,662 |
| Feb 17, 2026 | Poulton Jeffrey V. | officer: EVP, Chief Financial Officer | Sell | 2,242 | $310.08 | $695.2K | 59,802 |
| Feb 17, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 1,959 | $310.08 | $607.4K | 31,769 |
| Feb 12, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,041 | $331.96 | $677.5K | 0 |
| Feb 12, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,242 | $310.08 | $695.2K | 0 |
| Feb 12, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,959 | $310.08 | $607.4K | 0 |
| Jan 14, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 1,450 | $362.63 | $525.8K | 25,025 |
| Jan 14, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 1,429 | $362.45 | $517.9K | 31,199 |
| Jan 11, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,290 | $370.33 | $848.1K | 0 |
| Jan 11, 2026 | Garg Pushkal | EVP Chief R&D | Sell | 1,510 | $362.87 | $547.9K | 0 |
| Jan 11, 2026 | Greenstreet Yvonne | Chief Executive Officer | Sell | 9,577 | $362.86 | $3.48M | 0 |
| Jan 11, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,780 | $362.87 | $1.01M | 0 |
| Jan 11, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 21 | $371.02 | $7.8K | 0 |
| Nov 26, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 1,121 | $445.12 | $499.0K | 0 |
| Nov 17, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 12,128 | $452.18 | $5.48M | 0 |
| Nov 12, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 25,650 | $452.75 | $11.61M | 0 |
| Oct 1, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,441 | $452.05 | $1.10M | 0 |
| Oct 1, 2025 | Garg Pushkal | EVP Chief R&D | Sell | 5,956 | $451.76 | $2.69M | 0 |
| Oct 1, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 8,924 | $452.05 | $4.03M | 0 |
| Oct 1, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 3,821 | $452.05 | $1.73M | 0 |
| Oct 1, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,405 | $452.05 | $635.1K | 0 |
| Sep 9, 2025 | Reitan Colleen F | Director | Sell | 18,000 | $467.60 | $8.42M | 0 |
| Aug 29, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 3,474 | $448.37 | $1.56M | 0 |
| Aug 18, 2025 | BONNEY MICHAEL W | Director | Sell | 11,250 | $450.00 | $5.06M | 0 |
| Aug 15, 2025 | Garg Pushkal | EVP Chief R&D | Sell | 2,851 | $455.89 | $1.30M | 0 |
| Aug 15, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 6,979 | $453.27 | $3.16M | 0 |
| Aug 15, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,274 | $453.27 | $1.03M | 0 |
| Aug 14, 2025 | Ausiello Dennis A | Director | Sell | 31,448 | $436.58 | $13.73M | 0 |
| May 30, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 50,937 | $305.00 | $15.54M | 0 |
| May 15, 2025 | BONNEY MICHAEL W | Director | Sell | 11,250 | $277.71 | $3.12M | 0 |
| Mar 24, 2025 | PYOTT DAVID E I | Director | Sell | 7,440 | $299.00 | $2.22M | 0 |
| Mar 21, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | 9,766 | $293.36 | $2.86M | 0 |
| Mar 3, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,755 | $242.94 | $669.3K | 0 |
| Mar 3, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | 2,556 | $242.92 | $620.9K | 0 |
| Mar 3, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 3,877 | $243.79 | $945.2K | 0 |
| Mar 3, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 1,263 | $243.78 | $307.9K | 0 |
| Mar 3, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 471 | $243.78 | $114.8K | 0 |
| Feb 28, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 496 | $241.69 | $119.9K | 0 |
| Feb 27, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | 935 | $241.69 | $226.0K | 0 |
| Feb 27, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 2,900 | $241.69 | $700.9K | 0 |
| Feb 27, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 796 | $241.70 | $192.4K | 0 |
Showing 1–50 of 131
1 / 3
ALNY Insider Buying Activity
The following table shows recent insider purchases of Alnylam Pharmaceuticals, Inc. (ALNY) stock reported via SEC Form 4 filings.
No insider buying activity found for ALNY in the last 12 months.
ALNY Insider Selling Activity
The following table shows recent insider sales of Alnylam Pharmaceuticals, Inc. (ALNY) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 7, 2026 | McLaughlin Melissa | officer: Chief Human Resources Officer | Sell | 3,910 | $325.92 | $1.27M | 13,088 |
| Mar 6, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 1,291 | $323.54 | $417.7K | 21,831 |
| Mar 6, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 4,713 | $323.53 | $1.52M | 23,300 |
| Mar 6, 2026 | Greenstreet Yvonne | director, officer: Chief Executive Officer | Sell | 2,933 | $323.08 | $947.6K | 98,493 |
| Mar 6, 2026 | Poulton Jeffrey V. | officer: EVP, Chief Financial Officer | Sell | 2,468 | $323.08 | $797.4K | 64,159 |
| Mar 6, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 2,309 | $323.08 | $746.0K | 36,500 |
| Mar 2, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 4,627 | $331.34 | $1.53M | 26,629 |
| Feb 17, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 4,000 | $321.24 | $1.28M | 23,305 |
| Feb 17, 2026 | Garg Pushkal | officer: EVP Chief R&D | Sell | 2,242 | $310.08 | $695.2K | 24,848 |
| Feb 17, 2026 | Greenstreet Yvonne | director, officer: Chief Executive Officer | Sell | 13,916 | $310.08 | $4.32M | 85,662 |
| Feb 17, 2026 | Poulton Jeffrey V. | officer: EVP, Chief Financial Officer | Sell | 2,242 | $310.08 | $695.2K | 59,802 |
| Feb 17, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 1,959 | $310.08 | $607.4K | 31,769 |
| Feb 12, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,041 | $331.96 | $677.5K | 0 |
| Feb 12, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,242 | $310.08 | $695.2K | 0 |
| Feb 12, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,959 | $310.08 | $607.4K | 0 |
| Jan 14, 2026 | Fitzgerald Kevin Joseph | officer: CSO & EVP, Head of Research | Sell | 1,450 | $362.63 | $525.8K | 25,025 |
| Jan 14, 2026 | Tanguler Tolga | officer: EVP, Chief Commercial Officer | Sell | 1,429 | $362.45 | $517.9K | 31,199 |
| Jan 11, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,290 | $370.33 | $848.1K | 0 |
| Jan 11, 2026 | Garg Pushkal | EVP Chief R&D | Sell | 1,510 | $362.87 | $547.9K | 0 |
| Jan 11, 2026 | Greenstreet Yvonne | Chief Executive Officer | Sell | 9,577 | $362.86 | $3.48M | 0 |
| Jan 11, 2026 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,780 | $362.87 | $1.01M | 0 |
| Jan 11, 2026 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 21 | $371.02 | $7.8K | 0 |
| Nov 26, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 1,121 | $445.12 | $499.0K | 0 |
| Nov 17, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 12,128 | $452.18 | $5.48M | 0 |
| Nov 12, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 25,650 | $452.75 | $11.61M | 0 |
| Oct 1, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,441 | $452.05 | $1.10M | 0 |
| Oct 1, 2025 | Garg Pushkal | EVP Chief R&D | Sell | 5,956 | $451.76 | $2.69M | 0 |
| Oct 1, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 8,924 | $452.05 | $4.03M | 0 |
| Oct 1, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 3,821 | $452.05 | $1.73M | 0 |
| Oct 1, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 1,405 | $452.05 | $635.1K | 0 |
| Sep 9, 2025 | Reitan Colleen F | Director | Sell | 18,000 | $467.60 | $8.42M | 0 |
| Aug 29, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 3,474 | $448.37 | $1.56M | 0 |
| Aug 18, 2025 | BONNEY MICHAEL W | Director | Sell | 11,250 | $450.00 | $5.06M | 0 |
| Aug 15, 2025 | Garg Pushkal | EVP Chief R&D | Sell | 2,851 | $455.89 | $1.30M | 0 |
| Aug 15, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 6,979 | $453.27 | $3.16M | 0 |
| Aug 15, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 2,274 | $453.27 | $1.03M | 0 |
| Aug 14, 2025 | Ausiello Dennis A | Director | Sell | 31,448 | $436.58 | $13.73M | 0 |
| May 30, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 50,937 | $305.00 | $15.54M | 0 |
| May 15, 2025 | BONNEY MICHAEL W | Director | Sell | 11,250 | $277.71 | $3.12M | 0 |
| Mar 24, 2025 | PYOTT DAVID E I | Director | Sell | 7,440 | $299.00 | $2.22M | 0 |
| Mar 21, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | 9,766 | $293.36 | $2.86M | 0 |
| Mar 3, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 2,755 | $242.94 | $669.3K | 0 |
| Mar 3, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | 2,556 | $242.92 | $620.9K | 0 |
| Mar 3, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 3,877 | $243.79 | $945.2K | 0 |
| Mar 3, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 1,263 | $243.78 | $307.9K | 0 |
| Mar 3, 2025 | Tanguler Tolga | EVP, Chief Commercial Officer | Sell | 471 | $243.78 | $114.8K | 0 |
| Feb 28, 2025 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 496 | $241.69 | $119.9K | 0 |
| Feb 27, 2025 | Garg Pushkal | CMO & EVP Dev & Med Affairs | Sell | 935 | $241.69 | $226.0K | 0 |
| Feb 27, 2025 | Greenstreet Yvonne | Chief Executive Officer | Sell | 2,900 | $241.69 | $700.9K | 0 |
| Feb 27, 2025 | Poulton Jeffrey V. | EVP, Chief Financial Officer | Sell | 796 | $241.70 | $192.4K | 0 |
ALNY Insiders
Similar Stocks to ALNY
VRTX
Vertex Pharmaceuticals Incorporated
$430.93+1.13%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$747.97+0.47%
$77.87B
INSM
Insmed Incorporated
$135.28-0.51%
$30.79B
RVMD
Revolution Medicines, Inc.
$143.11+8.86%
$29.51B
UTHR
United Therapeutics Corporation
$566.02-0.17%
$25.13B
MRNA
Moderna, Inc.
$47.49-2.44%
$21.42B
RPRX
Royalty Pharma plc
$49.81+0.32%
$21.20B
ROIV
Roivant Sciences Ltd.
$27.95+0.38%
$20.96B